Isotretinoin Drugs Market – Forecast till 2027

Table of Contents

TABLE OF CONTENTS 1 EXECUTIVE SUMMARY 2 MARKET INTRODUCTION 2.1 DEFINITION 2.2 SCOPE OF THE STUDY 2.3 RESEARCH OBJECTIVE 2.4 MARKET STRUCTURE 2.5 ASSUMPTIONS & LIMITATIONS 3 RESEARCH METHODOLOGY 3.1 DATA MINING 3.2 SECONDARY RESEARCH 3.3 PRIMARY RESEARCH 3.4 BREAKDOWN OF PRIMARY RESPONDENTS 3.5 FORECASTING TECHNIQUES 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 3.6.1 BOTTOM-UP APPROACH 3.6.2 TOP-DOWN APPROACH 3.7 DATA TRIANGULATION 3.8 VALIDATION 4 MARKET DYNAMICS 4.1 OVERVIEW 4.2 DRIVERS 4.2.1 INCREASING PREVALENCE OF ACNE AMONG TEENS AND YOUNG ADULTS 4.2.2 INCREASING INCIDENCE OF NEUROBLASTOMA 4.3 RESTRAINT 4.3.1 CONCERNS PERTAINING TO DRUG SIDE EFFECTS 4.4 OPPORTUNITY 4.4.1 INTRODUCTION OF NEW MICRONIZED FORMATION FOR SEVERE RECALCITRANT NODULAR ACNE TREATMENT 5 MARKET FACTOR ANALYSIS 5.1 VALUE CHAIN ANALYSIS 5.1.1 R&D 5.1.2 MANUFACTURING 5.1.3 DISTRIBUTION & SALES 5.1.4 POST-SALES MONITORING 5.2 PORTER’S FIVE FORCES MODEL 5.2.1 THREAT OF NEW ENTRANTS 5.2.2 BARGAINING POWER OF SUPPLIERS 5.2.3 THREAT OF SUBSTITUTES 5.2.4 BARGAINING POWER OF BUYERS 5.2.5 INTENSITY OF RIVALRY 5.3 IMPACT OF COVID-19 ON ISOTRETINOIN DRUGS MARKET 5.3.1 IMPACT ON SUPPLY CHAIN 5.3.2 IMPACT ON THE ISOTRETINOIN DRUGS MARKET 5.3.3 IMPACT ON GDP AND HEALTHCARE EXPENDITURE 5.4 OFF LABEL USAGE OF ISOTRETINOIN CAPSULES 5.5 BY INDICAITION ANALYSIS ON PRESCRIBED PERSONNEL AND DOSAGE 6 GLOBAL ISOTRETINOIN DRUGS MARKET, BY FORM 6.1 OVERVIEW 6.2 CAPSULE 6.3 INJECTION 7 GLOBAL ISOTRETINOIN DRUGS MARKET, BY INDICATION 7.1 OVERVIEW 7.2 SEVERE ACNE 7.3 SQUAMOUS CELL CARCINOMA 7.4 CUTANEOUS T-CELL LYMPHOMA 7.5 NEUROBLASTOMA 7.6 HARLEQUIN ICHTHYOSIS 7.7 XERODERMA PIGMENTOSUM 7.8 FIBRODYSPLASIA OSSIFICANS PROGRESSIVA 7.9 OTHERS 8 GLOBAL ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL 8.1 OVERVIEW 8.2 HOSPITAL PHARMACIES 8.3 RETAIL PHARMACIES 8.4 ONLINE PHARMACIES 9 GLOBAL ISOTRETINOIN DRUGS MARKET, BY REGION 9.1 OVERVIEW 9.2 NORTH AMERICA 9.2.1 US 9.2.2 CANADA 9.3 EUROPE 9.3.1 GERMANY 9.3.2 FRANCE 9.3.3 UK 9.3.4 ITALY 9.3.5 RUSSIA 9.3.6 SPAIN 9.3.7 UKRAINE 9.3.8 REST OF EUROPE 9.4 ASIA-PACIFIC 9.4.1 CHINA 9.4.2 INDIA 9.4.3 JAPAN 9.4.4 SOUTH KOREA 9.4.5 AUSTRALIA 9.4.6 REST OF ASIA-PACIFIC 9.5 REST OF THE WORLD 9.5.1 MIDDLE EAST 9.5.2 AFRICA 9.5.3 LATIN AMERICA 10 COMPETITIVE LANDSCAPE 10.1 OVERVIEW 10.2 COMPETITIVE BENCHMARKING 10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL ISOTRETINOIN DRUGS MARKET 10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL ISOTRETINOIN DRUGS MARKET 10.5 KEY DEVELOPMENT ANALYSIS 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 10.6.1 PRODUCT LAUNCHES/PRODUCT APPROVALS 10.6.2 EXPANSIONS 10.7 FINANCIAL MATRIX 10.7.1 SALES (USD MILLION), 2020 10.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2020 11 COMPANY PROFILES 11.1 DOUGLAS PHARMACEUTICALS LIMITED 11.1.1 COMPANY OVERVIEW 11.1.2 FINANCIAL OVERVIEW 11.1.3 PRODUCTS/SERVICES OFFERED 11.1.4 KEY DEVELOPMENTS 11.1.5 SWOT ANALYSIS 11.1.6 KEY STRATEGIES 11.2 TEVA PHARMACEUTICAL INDUSTRIES LTD 11.2.1 COMPANY OVERVIEW 11.2.2 FINANCIAL OVERVIEW 11.2.3 PRODUCTS/SERVICES OFFERED 11.2.4 KEY DEVELOPMENTS 11.2.5 SWOT ANALYSIS 11.2.6 KEY STRATEGIES 11.3 AKORN OPERATING COMPANY LLC 11.3.1 COMPANY OVERVIEW 11.3.2 FINANCIAL OVERVIEW 11.3.3 PRODUCTS/SERVICES OFFERED 11.3.4 KEY DEVELOPMENTS 11.3.5 KEY STRATEGIES 11.4 DR. REDDY’S LABORATORIES LTD 11.4.1 COMPANY OVERVIEW 11.4.2 FINANCIAL OVERVIEW 11.4.3 PRODUCTS/SERVICES OFFERED 11.4.4 KEY DEVELOPMENTS 11.4.5 SWOT ANALYSIS 11.4.6 KEY STRATEGIES 11.5 F. HOFFMAN LA ROCHE LTD 11.5.1 COMPANY OVERVIEW 11.5.2 FINANCIAL OVERVIEW 11.5.3 PRODUCTS/SERVICES OFFERED 11.5.4 KEY DEVELOPMENTS 11.5.5 SWOT ANALYSIS 11.5.6 KEY STRATEGIES 11.6 MYLAN NV 11.6.1 COMPANY OVERVIEW 11.6.2 FINANCIAL OVERVIEW 11.6.3 PRODUCTS/SERVICES OFFERED 11.6.4 KEY DEVELOPMENTS 11.6.5 KEY STRATEGIES 11.7 SUN PHARMACEUTICALS 11.7.1 COMPANY OVERVIEW 11.7.2 FINANCIAL OVERVIEW 11.7.3 PRODUCTS OFFERED 11.7.4 KEY DEVELOPMENTS 11.7.5 SWOT ANALYSIS 11.7.6 KEY STRATEGIES 11.8 CIPHER PHARMACEUTICALS INC. 11.8.1 COMPANY OVERVIEW 11.8.2 FINANCIAL ANALYSIS 11.8.3 PRODUCTS OFFERED 11.8.4 KEY DEVELOPMENTS 11.8.5 KEY STRATEGIES 11.9 GLAXOSMITHKLINE PLC 11.9.1 COMPANY OVERVIEW 11.9.2 FINANCIAL ANALYSIS 11.9.3 PRODUCTS OFFERED 11.9.4 KEY DEVELOPMENTS 11.9.5 SWOT ANALYSIS 11.9.6 KEY STRATEGIES 11.10 CHONGQING HUAPONT 11.10.1 COMPANY OVERVIEW 11.10.2 FINANCIAL ANALYSIS 11.10.3 PRODUCTS OFFERED 11.10.4 KEY DEVELOPMENTS 11.10.5 KEY STRATEGIES 11.11 CATALENT PHARMA SOLUTIONS 11.11.1 COMPANY OVERVIEW 11.11.2 FINANCIAL ANALYSIS 11.11.3 PRODUCTS OFFERED 11.11.4 KEY DEVELOPMENTS 11.11.5 KEY STRATEGIES 12 APPENDIX 12.1 REFERENCES 12.2 RELATED REPORTS